GlassScriptPhysician profile
Linda C Wang
NPI 1063479756
$5,095.05
in general payments reported to CMS, 2019-2025
31 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $372 · 2021: $856 · 2022: $986 · 2023: $477 · 2024: $440 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.67 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,092.17 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $883.93 | 2019-2025 | Libtayo, Dupixent |
| Incyte Corporation | $558.93 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $474.33 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $434.96 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Galderma Laboratories, L.P. | $338.41 | 2019-2025 | Aklief |
| Genzyme Corporation | $192.46 | 2019-2025 | |
| Leo Pharma INC. | $138.68 | 2019-2022 | |
| Sebela Pharmaceuticals INC. | $113.08 | 2022-2023 | Naftin |
| Janssen Biotech, INC. | $94.99 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $93.84 | 2021-2023 | Winlevi, Absorica Ld |
| Merz North America, INC. | $75.80 | 2019-2021 | |
| Amgen INC. | $70.11 | 2021-2023 | Otezla |
| Dermira, INC. | $64.30 | 2019-2021 | |
| Almirall LLC | $45.88 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $43.88 | 2025 | Vtama |
| Journey Medical Corporation | $42.93 | 2022-2025 | |
| Ucb, INC. | $42.66 | 2021 | |
| Medline Industries LP | $35.41 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.65 | 2022-2023 | Sotyktu |
| Abbvie INC. | $27.06 | 2022 | |
| Mission Pharmacal Company | $26.68 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $23.34 | 2019 | |
| Biofrontera INC. | $20.51 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $19.92 | 2025 | |
| Vyne Pharmaceuticals INC. | $19.81 | 2020 | |
| Dermavant Sciences, INC. | $19.39 | 2024 | Vtama |
| Dusa Pharmaceuticals, INC. | $19.15 | 2019 | |
| Hill Dermaceuticals, INC. | $19.02 | 2021 | |
| Glenmark Therapeutics INC. | $16.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.77 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.